The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Eli Lilly expands oncology and neuroscience collaborations with OmniAb and Amplia Therapeutics
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 18, 6:29 PM EDT

Eli Lilly expands oncology and neuroscience collaborations with OmniAb and Amplia Therapeutics

The pharmaceutical company announced new research partnerships spanning ion channel drug discovery and a trial collaboration in KRAS G12C-mutant lung cancer, indicating continued investment in both neuroscience and precision oncology.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly is adding to its external research network, announcing new global collaboration deals aimed at drug discovery in neuroscience and a separate clinical trial partnership in oncology. The moves, described in a report published by Yahoo Finance on Aug. 18, come as large drug developers increasingly rely on outside expertise and platforms to feed early-stage pipelines.

In neuroscience, Lilly said it entered a global collaboration with OmniAb, a deal focused on ion channel drug discovery. Ion channels are proteins embedded in cell membranes that control the flow of ions, and they are a long-running target class in neurological and psychiatric drug research. A collaboration of this type typically involves joint work to identify and optimize molecules that can modulate those channels, with the goal of generating candidates that Lilly can advance.

For oncology, Lilly disclosed a trial partnership with Amplia Therapeutics tied to KRAS G12C-mutant lung cancer. KRAS is a gene frequently altered in cancers, and the G12C mutation is one specific change that has been the target of a growing set of targeted therapies in recent years. A trial collaboration suggests Lilly expects to evaluate a therapeutic approach in patients with that molecular subtype of lung cancer, though the specifics were not detailed in the Yahoo Finance report.

The company’s announcement also frames the partnerships as part of Lilly’s broader effort to build differentiated assets across therapeutic areas. Rather than presenting these deals as late-stage or near-term products, the language in the report emphasizes discovery and trial collaboration structures, which are commonly used to share risk and accelerate early development.

While the announcement identifies the collaborators and broad therapeutic focus areas, key deal terms were not provided in the report. That includes what Lilly and its partners will contribute to costs and resources, whether Lilly will have exclusive rights to any resulting candidates, and any milestone payments or regulatory and commercialization arrangements.

On the clinical side, the report did not specify the trial phase, the study design, the endpoints being targeted, or how patient enrollment would be managed. It also did not state whether Amplia Therapeutics is supplying a particular investigational agent, whether Lilly is contributing a compound or platform, or how the two efforts will be integrated in the protocol.

Sector context matters because partnerships have become a central feature of how pharma expands pipelines, especially in areas that are technically complex. Ion channel drug discovery can require strong capability in biologics or chemistry and careful pharmacology design, while KRAS-driven oncology trials depend heavily on patient selection and biomarker strategy.

Investors and analysts are likely to watch for clearer disclosure in future filings or press releases that specify development timelines, expected data readouts, and whether the programs are positioned as new internal growth areas or extensions of existing strategies. Next, Lilly’s subsequent communications may also clarify the regulatory pathway and how these collaborations fit into the company’s overall oncology and neuroscience priorities.

Why It Matters

  • These partnerships indicate Lilly continues to source early scientific and development capabilities from specialized external partners.
  • Ion channel drug discovery reflects sustained interest in neuroscience targets where mechanism and safety profiling can be difficult and resource-intensive.
  • A KRAS G12C lung cancer trial partnership underscores that precision oncology and mutation-defined patient populations remain a key growth area.
  • The lack of publicly disclosed timelines and trial details means the near-term impact on Lilly’s pipeline is not yet measurable from the announcement alone.

Sources

Key Facts

  • Eli Lilly announced new collaboration activities spanning neuroscience and lung cancer research.
  • Lilly’s neuroscience collaboration with OmniAb is focused on ion channel drug discovery.
  • Lilly’s oncology collaboration with Amplia Therapeutics involves a trial partnership in KRAS G12C-mutant lung cancer.
  • The report characterized the efforts as global collaborations and trial collaborations rather than specific, fully disclosed late-stage programs.
  • The Yahoo Finance report did not provide financial terms, deal economics, trial phase, or detailed study design information.

Healthcare Related

Eli Lilly expands oncology and neuroscience collaborations with OmniAb and Amplia Therapeutics | The Apex Times